Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 554

1.

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007477. doi: 10.1002/14651858.CD007477.pub2. Review.

PMID:
20687088
2.

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Meerpohl JJ, Schell LK, Rücker G, Motschall E, Fleeman N, Niemeyer CM, Bassler D.

Cochrane Database Syst Rev. 2014 May 27;5:CD007477. [Epub ahead of print]

PMID:
24893174
3.

Deferasirox for managing iron overload in people with thalassaemia.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007476. doi: 10.1002/14651858.CD007476.pub2. Review.

PMID:
22336831
4.

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.

Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Review.

PMID:
23963793
5.

Deferasirox for managing iron overload in people with thalassaemia.

Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.

Cochrane Database Syst Rev. 2017 Aug 15;8:CD007476. doi: 10.1002/14651858.CD007476.pub3. [Epub ahead of print] Review.

PMID:
28809446
6.

Deferasirox for managing iron overload in people with myelodysplastic syndrome.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD007461. doi: 10.1002/14651858.CD007461.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD007461.

PMID:
21069694
7.

Oral deferiprone for iron chelation in people with thalassaemia.

Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.

Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004839. doi: 10.1002/14651858.CD004839.pub3. Review.

PMID:
23966105
8.

Oral deferiprone for iron chelation in people with thalassaemia.

Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004839. Review. Update in: Cochrane Database Syst Rev. 2013;8:CD004839.

PMID:
17636775
9.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cell Investigators.

Br J Haematol. 2007 Feb;136(3):501-8.

10.

Deferasirox for managing iron overload in people with myelodysplastic syndrome.

Meerpohl JJ, Schell LK, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.

Cochrane Database Syst Rev. 2014 Oct 28;(10):CD007461. doi: 10.1002/14651858.CD007461.pub3. Review.

PMID:
25348770
11.

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.

Br J Haematol. 2011 Aug;154(3):387-97. doi: 10.1111/j.1365-2141.2011.08720.x. Epub 2011 May 19.

12.

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.

Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121. doi: 10.3310/hta13010. Review.

13.

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004450. Review. Update in: Cochrane Database Syst Rev. 2013;8:CD004450.

PMID:
16235363
14.

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.

Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B; study CICL670A2201 investigators.

Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.

15.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
16.

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y.

Blood. 2011 Jul 28;118(4):884-93. doi: 10.1182/blood-2010-11-316646. Epub 2011 May 31. Erratum in: Blood. 2011 Nov 3;118(18):5060.

17.

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC.

Cochrane Database Syst Rev. 2017 Jan 17;1:CD003146. doi: 10.1002/14651858.CD003146.pub3. Review.

PMID:
28094851
18.

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF.

Acta Haematol. 2008;119(3):133-41. doi: 10.1159/000125550. Epub 2008 Apr 11.

PMID:
18408362
19.

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.

Cappellini MD, Taher A.

Expert Opin Pharmacother. 2008 Sep;9(13):2391-402. doi: 10.1517/14656566.9.13.2391 . Review.

PMID:
18710363
20.

Deferasirox.

Stumpf JL.

Am J Health Syst Pharm. 2007 Mar 15;64(6):606-16. Review.

PMID:
17353569

Supplemental Content

Support Center